AR039633A2 - Uso de un compuesto tipo cabergolina para preparar un medicamento para el tratamiento de la fibromialgia y el sindrome de fatiga cronica - Google Patents

Uso de un compuesto tipo cabergolina para preparar un medicamento para el tratamiento de la fibromialgia y el sindrome de fatiga cronica

Info

Publication number
AR039633A2
AR039633A2 ARP030101259A ARP030101259A AR039633A2 AR 039633 A2 AR039633 A2 AR 039633A2 AR P030101259 A ARP030101259 A AR P030101259A AR P030101259 A ARP030101259 A AR P030101259A AR 039633 A2 AR039633 A2 AR 039633A2
Authority
AR
Argentina
Prior art keywords
cabergoline
prepare
treatment
fibromialgia
chronic fatigue
Prior art date
Application number
ARP030101259A
Other languages
English (en)
Original Assignee
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Upjohn Co filed Critical Upjohn Co
Publication of AR039633A2 publication Critical patent/AR039633A2/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/451Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4738Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/48Ergoline derivatives, e.g. lysergic acid, ergotamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)

Abstract

El uso de un compuesto de tipo cabergolina, o de una de sus sales farmacéuticamente aceptables, que es para preparar un medicamento para el tratamiento de síntomas del síndrome de fibromialgia o síndrome de fatiga crónica. Reivindicación 3: el uso de un compuesto de la reivindicación 1, caracterizado porque dicho compuesto es un compuesto de la fórmula (C) o una de sus sales farmacéuticamente aceptables.
ARP030101259A 2000-04-21 2003-04-10 Uso de un compuesto tipo cabergolina para preparar un medicamento para el tratamiento de la fibromialgia y el sindrome de fatiga cronica AR039633A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19895900P 2000-04-21 2000-04-21
US20056900P 2000-04-28 2000-04-28

Publications (1)

Publication Number Publication Date
AR039633A2 true AR039633A2 (es) 2005-03-02

Family

ID=26894316

Family Applications (3)

Application Number Title Priority Date Filing Date
ARP010101861A AR028355A1 (es) 2000-04-21 2001-04-20 Compuestos para el tratamiento de la fibromialgia y el sindrome de fatiga cronica
ARP030101259A AR039633A2 (es) 2000-04-21 2003-04-10 Uso de un compuesto tipo cabergolina para preparar un medicamento para el tratamiento de la fibromialgia y el sindrome de fatiga cronica
ARP030101258A AR039632A2 (es) 2000-04-21 2003-04-10 Uso de un compuesto tipo amina heterociclica para preparar un medicamento para el tratamiento de la fibromialgia y el sindrome de fatiga cronica

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP010101861A AR028355A1 (es) 2000-04-21 2001-04-20 Compuestos para el tratamiento de la fibromialgia y el sindrome de fatiga cronica

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP030101258A AR039632A2 (es) 2000-04-21 2003-04-10 Uso de un compuesto tipo amina heterociclica para preparar un medicamento para el tratamiento de la fibromialgia y el sindrome de fatiga cronica

Country Status (16)

Country Link
US (3) US6448258B2 (es)
EP (1) EP1274430B1 (es)
JP (1) JP2004502650A (es)
KR (1) KR20040007215A (es)
CN (3) CN1450898A (es)
AR (3) AR028355A1 (es)
AT (1) ATE312608T1 (es)
AU (2) AU5311401A (es)
BR (1) BR0110210A (es)
CA (1) CA2405565A1 (es)
DE (1) DE60115872T2 (es)
DK (1) DK1274430T3 (es)
ES (1) ES2253370T3 (es)
NZ (3) NZ531172A (es)
PE (1) PE20011212A1 (es)
WO (1) WO2001081343A2 (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE46117E1 (en) 1999-12-22 2016-08-23 Teva Pharmaceuticals International Gmbh Modulators of dopamine neurotransmission
CA2404704A1 (en) * 2000-04-21 2001-11-22 David W. Robertson Treatment of fibromyalgia and chronic fatigue syndrome
AR033520A1 (es) * 2000-04-27 2003-12-26 Upjohn Co (5r)-(metilamino) -5,6-dihidro-4h-imidazo[4,5,1-ij] quinolin-2(1h)-tiona
MXPA03001472A (es) * 2000-08-16 2003-06-06 Upjohn Co Compuestos para el tratamiento de trastornos adictivos.
AR031152A1 (es) 2000-10-31 2003-09-10 Upjohn Co Tratamientos nuevos para el sindrome de piernas inquietas
CA2500919A1 (en) * 2002-10-04 2004-04-22 Pharmacia Corporation Compositions and methods for treating sexual dysfunction
BR0314526A (pt) * 2002-10-04 2005-07-26 Pharmacia Corp Composições farmacêuticas para o tratamento do mal de parkinson
JP2009501184A (ja) 2005-07-13 2009-01-15 エフ.ホフマン−ラ ロシュ アーゲー 5−ht6、5−ht24としてのベンゾイミダゾール誘導体
TWI392670B (zh) * 2006-06-22 2013-04-11 Ucb Pharma Gmbh 經取代的2-胺基萘滿之於製造用於預防、減緩及/或治療各種類型疼痛之藥物上的用途
ES2332645B1 (es) * 2009-06-30 2010-10-18 Grifols, S.A. Utilizacion de alfa-1-antitripsina para la preparacion de medicamentos para el tratamiento del sindrome de fatiga cronica.
DK2618826T3 (en) * 2010-09-20 2016-08-01 A Carlsson Res Ab Phenylpiperdine FOR TREATMENT OF DEMENTIA
EA035469B1 (ru) 2013-03-15 2020-06-22 Инсайт Холдингс Корпорейшн Трициклические гетероциклы как ингибиторы белков бэт
JP2016523964A (ja) 2013-07-08 2016-08-12 インサイト・ホールディングス・コーポレイションIncyte Holdings Corporation Betタンパク質阻害剤としての三環式複素環
US9399640B2 (en) 2013-11-26 2016-07-26 Incyte Corporation Substituted pyrrolo[2,3-c]pyridines and pyrazolo[3,4-c]pyridines as BET protein inhibitors
US9315501B2 (en) 2013-11-26 2016-04-19 Incyte Corporation Bicyclic heterocycles as BET protein inhibitors
US9309246B2 (en) 2013-12-19 2016-04-12 Incyte Corporation Tricyclic heterocycles as BET protein inhibitors
MX2016013851A (es) 2014-04-23 2017-07-14 Incyte Corp 1h-pirrolo[2,3-c]piridin-7(6h)-onas y pirazolo[3,4-c]piridin-7(6h) -onas como inhibidores de proteinas de bromodominio y extra terminal (bet).
DE102014008742A1 (de) * 2014-06-12 2015-12-17 Daimler Ag Separator für einen elektrochemischen Speicher, Verfahren zur Herstellung eines Elektrodenmaterials sowie elektrochemischer Energiespeicher
EP3194406B8 (en) 2014-09-15 2021-03-31 Incyte Corporation Tricyclic heterocycles for use as bet protein inhibitors
WO2016180879A1 (en) * 2015-05-13 2016-11-17 A. Carlsson Research Ab Treatment of debilitating fatigue
US20170121347A1 (en) 2015-10-29 2017-05-04 Incyte Corporation Amorphous solid form of a bet protein inhibitor
CR20220651A (es) 2016-06-20 2023-01-23 Incyte Corp FORMAS SOLIDAS CRISTALINAS DE UN INHIBIDOR DE BET (Divisional expediente 2019-0027.)
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4526892A (en) * 1981-03-03 1985-07-02 Farmitalia Carlo Erba, S.P.A. Dimethylaminoalkyl-3-(ergoline-8'βcarbonyl)-ureas
US5273975A (en) 1989-06-09 1993-12-28 The Upjohn Company Heterocyclic amines having central nervous system activity
JP2955358B2 (ja) 1989-06-09 1999-10-04 ファルマシア・アンド・アップジョン・カンパニー 中枢神経系活性を有する複素環系アミン
EP0641320B1 (en) * 1991-04-17 2001-05-30 PHARMACIA & UPJOHN COMPANY Substituted (s)-3-phenylpiperidine derivatives, their preparation and their use as dopamine autoreceptor antagonists
AU684808B2 (en) * 1993-07-27 1998-01-08 Pharmacia & Upjohn Company Heterocyclic amines having central nervous system activity
JPH1053525A (ja) * 1996-06-06 1998-02-24 Bitakain Seiyaku Kk 疼痛治療剤
US6455564B1 (en) 1999-01-06 2002-09-24 Pharmacia & Upjohn Company Method of treating sexual disturbances
WO2000054773A1 (en) * 1999-03-12 2000-09-21 Nitromed, Inc. Dopamine agonists in combination with nitric oxide donors, compositions and methods of use
PT1459750E (pt) 1999-07-01 2005-08-31 Pharmacia & Upjohn Co Llc (s,s)- reboxetina para tratar a fibromialgia ou outras perturbacoes somatoformes
DE19938823A1 (de) 1999-08-19 2001-02-22 Boehringer Ingelheim Pharma Medikamentöse Behandlung des Restless Leg Syndroms
WO2001015677A2 (en) 1999-08-31 2001-03-08 Alcon Laboratories, Inc. Use of 5-ht1b/1d agonists to treat otic pain

Also Published As

Publication number Publication date
US6555548B2 (en) 2003-04-29
JP2004502650A (ja) 2004-01-29
US6448258B2 (en) 2002-09-10
CN1554343A (zh) 2004-12-15
EP1274430B1 (en) 2005-12-14
NZ531171A (en) 2005-03-24
US20020004510A1 (en) 2002-01-10
AU2001253114B2 (en) 2005-08-25
NZ531172A (en) 2005-07-29
CN1554341A (zh) 2004-12-15
DE60115872D1 (de) 2006-01-19
DK1274430T3 (da) 2006-02-13
US20030191149A1 (en) 2003-10-09
KR20040007215A (ko) 2004-01-24
EP1274430A2 (en) 2003-01-15
CN1450898A (zh) 2003-10-22
NZ522112A (en) 2004-10-29
WO2001081343A3 (en) 2002-02-28
AU5311401A (en) 2001-11-07
BR0110210A (pt) 2003-01-28
ATE312608T1 (de) 2005-12-15
CA2405565A1 (en) 2001-11-01
AR039632A2 (es) 2005-03-02
US20020143010A1 (en) 2002-10-03
ES2253370T3 (es) 2006-06-01
DE60115872T2 (de) 2006-07-13
WO2001081343A2 (en) 2001-11-01
PE20011212A1 (es) 2001-11-21
AR028355A1 (es) 2003-05-07

Similar Documents

Publication Publication Date Title
AR039633A2 (es) Uso de un compuesto tipo cabergolina para preparar un medicamento para el tratamiento de la fibromialgia y el sindrome de fatiga cronica
AR058163A1 (es) Medicamentos exhaltadores del deseo sexual que comprenden derivados de benzimidazolona
HN2002000275A (es) Derivados de 1,8 naftiridina y su uso para el tratamiento de diabetes y trastornos relacionados
ES2178943B1 (es) Uso de compuestos organicos en el tratamiento de enfermedad pulmonar obstructiva cronica.
CL2020002512A1 (es) Tratamiento de la hidradenitis supurativa mediante el uso de inhibidores de jak.
BR0315337A (pt) Composto, formulação farmacêutica, e, método para tratar câncer
GT200600163A (es) Nuevas combinaciones terapeuticas para el tratamiento o la prevencion de la depresion
CL2008003938A1 (es) Uso de escitalopram o de una sal farmaceuticamente aceptable del mismo para preparar un medicamento util en el tratamiento del desorden de estres postraumatico (divisional sol. 1799-00).
CL2007001752A1 (es) Compuesto 4-[5(2-amino-etansulfonil)-isoquinolin-7-il]-fenolo una sal farmaceuticamente aceptable o un hidrato o la sal del mismo;composicion farmaceutica que comprende a dicho compuesto,composicion farmaceutica liofilizada;y uso del compuesto como antineiplasico y/o antiviral.
UY27296A1 (es) Composición farmacéutica que contiene mosaprida y pancreatina
CO5700723A2 (es) Uso de un derivado de amina ciclica especifico o de sus sales farmaceuticamente aceptables para tratar y prevenir la insuficiencia cardiaca
AR111374A1 (es) Uso de lik066 en pacientes con insuficiencia cardíaca
AR119158A1 (es) Tratamientos de angioedema hereditario
BRPI0212298B8 (pt) composição farmacêutica compreendendo gabapentina ou um análogo da mesma e (alfa)-aminoamida e seu uso analgésico
CO5200840A1 (es) Combinacion de sustancias activas con clonidina
BR0107628A (pt) l,2-diarilbenzimidazóis para tratamento de doenças que estão associadas a uma ativação microglial
AR052830A1 (es) Regimen de cladribina para tratar esclerosis multiple
UY27018A1 (es) Derivados de la pirimidina
AR026254A1 (es) El uso de una preparacion de liberacion controlada para la preparacion de un medicamento para aumentar la dosis o la exposicion sistemica de un farmaco queinhibe la fosfodiesterasa 4
ES2191942T3 (es) Nueva utilizacion de un antagonista especifico de los receptores 5ht2a.
AR029588A1 (es) Nueva forma (r)-n-[5-metil-8-(4-metilpiperazina-1-il)-1,2,3,4-tetrahidro-2-naftil]-4-morfolinobenzamida
PE20020387A1 (es) Uso de una combinacion de salmeterol y fluticasona
AR062784A1 (es) Tratmiento de los vertigos con acetil -l- leucina
CO2022004947A2 (es) Regímenes de dosificación para el tratamiento de pacientes con carcinoma de células escamosas avanzado localmente
UY39510A (es) Compuestos macrocíclicos y métodos para usarlos

Legal Events

Date Code Title Description
FB Suspension of granting procedure